MGNX
Macrogenics Inc

4,027
Mkt Cap
$109.44M
Volume
1.17M
52W High
$2.63
52W Low
$0.9896
PE Ratio
-1.43
MGNX Fundamentals
Price
$1.92
Prev Close
$1.73
Open
$1.73
50D MA
$1.69
Beta
1.44
Avg. Volume
1.04M
EPS (Annual)
-$1.07
P/B
1.63
Rev/Employee
$439,771.26
$39.31
Loading...
Loading...
News
all
press releases
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts
MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has been given a consensus rating of "Hold" by the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has...
MarketBeat·17d ago
News Placeholder
More News
News Placeholder
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Should You Sell?
MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts
Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities...
MarketBeat·1mo ago
News Placeholder
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
Zacks·1mo ago
News Placeholder
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above 50 Day Moving Average - What's Next?
MacroGenics (NASDAQ:MGNX) Shares Cross Above 50-Day Moving Average - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Zacks·2mo ago
News Placeholder
MacroGenics (NASDAQ:MGNX) Rating Lowered to "Hold" at Zacks Research
Zacks Research cut shares of MacroGenics from a "strong-buy" rating to a "hold" rating in a research note on Thursday...
MarketBeat·2mo ago
News Placeholder
MacroGenics (NASDAQ:MGNX) Shares Pass Above 50 Day Moving Average - Should You Sell?
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell...
MarketBeat·2mo ago
News Placeholder
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat reports. One equities...
MarketBeat·2mo ago
News Placeholder
EcoR1 Capital LLC Purchases New Shares in MacroGenics, Inc. $MGNX
EcoR1 Capital LLC acquired a new stake in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor...
MarketBeat·2mo ago
<
1
2
...
>

Latest MGNX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.